Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health Inks PGx Alliance with OncoMed

NEW YORK (GenomeWeb News) – Genomic Health said after the close of the market Wednesday that it will collaborate with OncoMed Pharmaceuticals in identifying biomarkers that can be applied to clinical development of certain OncoMed antibody cancer drugs.

OncoMed will provide Genomic Health with breast, prostate, colon, and lung tumor samples, and will include a subset of OncoMed's proprietary xenograft models derived from freshly resected human cancers. Genomic Health will use its next-generation sequencing capabilities to discover biomarkers that may help identify patients that are more likely to respond to cancer therapeutics that target the Notch, Wnt and other pathways critical to cancer stem cells.

"This collaboration supports our long-term vision and belief that molecular diagnostics are inherent for bringing quality, personalized care to all cancer patients from diagnosis through survivorship," Genomic Health Chief Medical Officer Steve Shak said in a statement.

Financial and other terms of the agreement were not disclosed.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.